Naphazoline

Naphazoline

Naphazoline

Chemical compound


Naphazoline is a medicine used as a decongestant, and a vasoconstrictor added to eye drops to relieve red eye. It has a rapid action in reducing swelling when applied to mucous membranes. It is a sympathomimetic agent with marked alpha adrenergic activity that acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion.

Quick Facts Clinical data, Trade names ...

It was patented in 1934 and came into medical use in 1942.[1]

Medical uses

Red eyes can be treated with naphazoline.

Nasal administration

Nasal decongestant.[2]

Ophthalmic drug administration

Eye drops (brand names Clear Eyes, and Cleari) narrowing swollen blood vessels (ophthalmic arteries, and ophthalmic veins) to relieve red eye.[2]

Temporary red eye can safely be treated when the cause of the redness is established (e.g. cannabis induced corneal vasodilation).[3] However, continuous use is not recommended without knowing an underlying condition.

Side effects

A few warnings and contraindications that apply to all naphazoline-containing substances intended for medicinal use are:

Nasal administration

Ophthalmic drug administration

Known side-effect:[5][6]

Contraindications

Pharmacology

Naphazoline is a mixed α1- and α2-adrenergic receptor agonist.[2]

Chemistry

The non-hydrochloride form of Naphazoline has the molecular formula C14H14N2 and a molar mass of 210.28 g/mol. The HCl salt form has a molar mass of 246.73 g/mol.

Society and culture

It is an active ingredient in several over-the-counter eye drop formulations including Clear Eyes, Rohto, Eucool, and Naphcon-A.[7]

Illicit use

The nasal or ophthalmic form of naphazoline has been abused by heroin or cocaine drug addicts.[8][9] It's used as CNS stimulant and vasoconstrictor to enhance primary drug effects.[9]


References

  1. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 552. ISBN 9783527607495.
  2. Yazulla S (September 2008). "Endocannabinoids in the retina: from marijuana to neuroprotection". Progress in Retinal and Eye Research. 27 (5): 501–526. doi:10.1016/j.preteyeres.2008.07.002. PMC 2584875. PMID 18725316.
  3. Zavala JA, Pereira ER, Zétola VH, Teive HA, Nóvak EM, Werneck LC (September 2004). "Hemorrhagic stroke after naphazoline exposition: case report". Arquivos de Neuro-Psiquiatria. 62 (3B): 889–891. doi:10.1590/S0004-282X2004000500030. PMID 15476091.
  4. Green SM (2008). "Ophthalmology: Naphazoline". Tarascon Pocket Pharmacopoeia 2009. Jones and Bartlett. ISBN 978-0-7637-6572-9.
  5. van Montfrans GA, van Steenwijk RP, Vyth A, Borst C (1981). "Intravenous naphazoline intoxication". Acta Medica Scandinavica. 209 (5): 429–430. doi:10.1111/j.0954-6820.1981.tb11622.x. PMID 7246278.
  6. "Naphazoline abuse". Reactions Weekly. 1815 (1): 251. 2020-08-01. doi:10.1007/s40278-020-81577-1. ISSN 1179-2051. S2CID 195174995.

Share this article:

This article uses material from the Wikipedia article Naphazoline, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.